Quit your YAPing: A new target for cancer therapy

Genes and Development

Volumn 26, Issue 12, 2012, Pages 1263-1267

  Stanger, Ben Z ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Chemical biology; Hippo signaling; Oncogene; YAP

Indexed keywords

TEAD TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; YAP TRANSCRIPTION FACTOR;

ARTICLE; CARCINOGENESIS; DNA BINDING; EMBRYO DEVELOPMENT; GENE AMPLIFICATION; HIPPO PATHWAY; HOMEOSTASIS; HUMAN; LIVER CANCER; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 84862606124     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.196501.112     Document Type: Article

References (27)

1. Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, Lonser RR. 2009. Neurofibromatosis type 2. Lancet 373: 1974-1986.
2. Baldwin C, Garnis C, Zhang L, Rosin MP, Lam WL. 2005. Multiple microalterations detected at high frequency in oral cancer. Cancer Res 65: 7561-7567.
3. Cai J, Zhang N, Zheng Y, de Wilde RF, Maitra A, Pan D. 2010. The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev 24: 2383-2388.
4. Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R, Brummelkamp TR. 2007. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 17: 2054-2060.
5. Chan SW, Lim CJ, Guo K, Ng CP, Lee I, Hunziker W, Zeng Q, Hong W. 2008. A role for TAZ in migration, invasion, and tumori-genesis of breast cancer cells. Cancer Res 68: 2592-2598.
6. Chan SW, Lim CJ, Chen L, Chong YF, Huang C, Song H, Hong W. 2010. The Hippo pathway in biological control and cancer development. J Cell Physiol 226: 928-939.
7. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A, Pan D. 2007. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 130: 1120-1133.
8. Drebin JA, Link VC, Weinberg RA, Greene MI. 1986. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Natl Acad Sci 83: 9129-9133.
9. Fernandez LA, Northcott PA, Dalton J, Fraga C, Ellison D, Angers S, Taylor MD, Kenney AM. 2009. YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes Dev 23: 2729-2741.
10. Grembecka J, He S, Shi A, Purohit T, Muntean AG, Sorenson RJ, Showalter HD, Murai MJ, Belcher AM, Hartley T, et al. 2012. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol 8: 277-284.
11. Halder G, Johnson RL. 2011. Hippo signaling: Growth control and beyond. Development 138: 9-22.
12. Justice RW, Zilian O, Woods DF, Noll M, Bryant PJ. 1995. The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev 9: 534-546.
13. Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, Zhao S, Xiong Y, Guan KL. 2008. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol 28: 2426-2436.
14. Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, Liu JO, Pan D. 2012. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the onco-genic activity of YAP. Genes Dev (this issue). doi: 10.1101/ gad.192856.112.
15. Michels S, Schmidt-Erfurth U. 2001. Photodynamic therapy with verteporfin: A new treatment in ophthalmology. Semin Ophthalmol 16: 201-206.
16. Modena P, Lualdi E, Facchinetti F, Veltman J, Reid JF, Minardi S, Janssen I, Giangaspero F, Forni M, Finocchiaro G, et al. 2006. Identification of tumor-specific molecular signatures in in-tracranial ependymoma and association with clinical characteristics. J Clin Oncol 24: 5223-5233.
17. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, Deng CX, Brugge JS, Haber DA. 2006. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci 103: 12405-12410.
18. Pan D. 2010. The hippo signaling pathway in development and cancer. Dev Cell 19: 491-505.
19. Sawada A, Kiyonari H, Ukita K, Nishioka N, Imuta Y, Sasaki H. 2008. Redundant roles of Tead1 and Tead2 in notochord development and the regulation of cell proliferation and survival. Mol Cell Biol 28: 3177-3189.
20. Snijders AM, Schmidt BL, Fridlyand J, Dekker N, Pinkel D, Jordan RC, Albertson DG. 2005. Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma. Oncogene 24: 4232-4242.
21. Xu T, Wang W, Zhang S, Stewart RA, Yu W. 1995. Identifying tumor suppressors in genetic mosaics: The Drosophila lats gene encodes a putative protein kinase. Development 121: 1053-1063.
22. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, et al. 2006. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125: 1253-1267.
23. Zhang N, Bai H, David KK, Dong J, Zheng Y, Cai J, Giovannini M, Liu P, Anders RA, Pan D. 2010. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell 19: 27-38.
24. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, et al. 2007. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 21: 2747-2761.
25. Zhao B, Li L, Lei Q, Guan KL. 2010a. The Hippo-YAP pathway in organ size control and tumorigenesis: An updated version. Genes Dev 24: 862-874.
26. Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. 2010b. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(b-TRCP). Genes Dev 24: 72-85.
27. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, et al. 2011. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478: 524-528.